{"id":1215,"date":"2023-10-19T19:06:06","date_gmt":"2023-10-19T19:06:06","guid":{"rendered":"https:\/\/bcchrmicro.wpengine.com\/?page_id=1215"},"modified":"2026-03-10T22:39:33","modified_gmt":"2026-03-10T22:39:33","slug":"publications","status":"publish","type":"page","link":"https:\/\/www.bcchr.ca\/brave-initiative\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"
\n\t
\n\t
\n\t
\n\t
\n\t<\/span>\n\tThe BRAvE Initiative<\/span><\/a><\/span>News<\/span><\/a><\/span><\/div>\n

Publications<\/h1>

Select publications from the BRAvE Initiative team.<\/p><\/div>\n

\n\t
\n\t<\/figure>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n
\n\t
\n\t
\n\t

Journals<\/h3>
    \n\tLorentzian A, Biegel JA, Ostrow DG, Rolf N, Liu CC, Rassekh SR, Deyell RJ, Triche T, Schultz KR, Rozmus J,\u00a0Reid GSD<\/strong>,\u00a0Lim CJ<\/strong>,\u00a0Lange PF<\/strong>,\u00a0Maxwell CA<\/strong>.\u00a0Tumor Variant Identification That Accounts for the Unique Molecular Landscape of Pediatric Malignancies<\/a>.\u00a0JNCI Cancer Spectr<\/em>. 2018 Oct;2(4):pky079. doi: 10.1093\/jncics\/pky079. Epub 2019 Jan 25. PMID: 30976750; PMCID: PMC6447067.<\/li>\n\n\tUzozie AC, Ergin EK, Rolf N, Tsui J, Lorentzian A, Weng SSH, Nierves L, Smith TG,\u00a0Lim CJ<\/strong>,\u00a0Maxwell CA<\/strong>,\u00a0Reid GSD<\/strong>,\u00a0Lange PF<\/strong>.\u00a0PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathways<\/a>.\u00a0J Exp Clin Cancer Res<\/em>. 2021 Mar 15; 40(1):96. doi: 10.1186\/s13046-021-01835-8. PMID: 33722259; PMCID: PMC7958471.<\/li>\n\n\t*Rolf N, Liu LYT, Tsang A,\u00a0Lange PF<\/strong>,\u00a0Lim CJ<\/strong>,\u00a0Maxwell CA<\/strong>, Vercauteren SM,\u00a0Reid GSD<\/strong>.\u00a0A cross-standardized flow cytometry platform to assess phenotypic stability in precursor B-cell acute lymphoblastic leukemia (B-ALL) xenografts<\/a>.\u00a0Cytometry A<\/em>. 2022 Jan;101(1):57-71. doi: 10.1002\/cyto.a.24473. Epub 2021 Jun 25. PMID: 34128309; PMCID: PMC9292200.
    *Featured as one of two \u201cmust-read\u201d articles in the monthly roundup of the European Journal of Immunology.\u00a0<\/em>    Dissecting phenotypic subpopulation complexity in childhood leukemia for PDX-based precision medicine approaches<\/a>.\u00a0Eur. J. Immunol<\/em>. (2021) 51(9):2114, DOI: 10.1002\/eji.202170094.<\/li>\n\n\tBarnabas GD, Goebeler V, Tsui J,\u00a0Bush JW<\/strong>,\u00a0Lange PF<\/strong>.\u00a0ASAP\u2500Automated Sonication-Free Acid-Assisted Proteomes\u2500from Cells and FFPE Tissues<\/a>.\u00a0Anal Chem<\/em>. 2023 Feb 14;95(6):3291-3299. doi: 10.1021\/acs.analchem.2c04264. Epub 2023 Feb 1. PMID: 36724070; PMCID: PMC9933881.<\/li>\n\n\tLorentzian AC, Rever J, Ergin EK, Guo M, Akella NM, Rolf N,\u00a0Lim CJ<\/strong>,\u00a0Reid GSD<\/strong>,\u00a0Maxwell CA<\/strong>,\u00a0Lange PF<\/strong>.\u00a0Targetable lesions and proteomes predict therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia<\/a>.\u00a0Nat Commun<\/em>. 2023 Nov 21;14(1):7161. doi: 10.1038\/s41467-023-42701-9. PMID: 37989729; PMCID: PMC10663560.<\/li>\n\n\tBarnabas GD, Bhat TA, Goebeler V, Leclair P, Azzam N, Melong N, Anderson C, Gom A, An S, Ergin EK, Shen Y, Mungall AJ, Mungall KL,\u00a0Maxwell CA<\/strong>,\u00a0Reid GSD<\/strong>, Hirst M, Jones S, Chan JA, Senger DL, Berman JN, Parker SJ,\u00a0Bush JW<\/strong>, Strahlendorf C, Deyell RJ,\u00a0Lim CJ<\/strong>,\u00a0Lange PF<\/strong>.\u00a0Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe<\/a>.\u00a0EMBO Mol Med<\/em>. 2025 Apr 1. doi.org\/10.1038\/s44321-025-00212-8<\/li>\n<\/ol>

    Meeting Abstracts<\/h2>
      \n\tUzozie A, Tsui J, Maxwell CA, Lim CJ, Reid G, and Lange PF. Integrated proteome, phospho-proteome and N terminome characterization of pediatric patient and matched engrafted leukemia. Canadian National Proteomics Network (CNPN) Conference, Montreal, QC. May, 2019 (Oral Presentation).<\/li>\n\n\tBarnabas GD, Bhat TA, Goebeler V, Maxwell CM, Reid GS, Senger D, Parker S, Bush J, Strahlendorf C, Deyell R, Lim CJ, Lange PF, and on behalf of the PROFYLE program. Prioritizing treatment targets for a rare pediatric malignancy using proteomics and personalized xenograft models within an actionable timeframe. 9th TFRI Scientific Meeting, Vancouver. Nov, 2022 (Poster)<\/li>\n\n\tBhat TA, Barnabas GD, Goebeler V, Leclair P, Maxwell CM, Deyell R, Strahlendorf C, Bush J, Reid GS, Lange PF, Lim CJ, on behalf of the PROFYLE program. Evaluating Targeted Drug Therapies for Pediatric Tumours Using the Chick Chorioallantoic Membrane (CAM) Xenograft Model. 9th TFRI Scientific Meeting, Vancouver. Nov, 2022 (Poster & Rapid-Fire Talk)<\/li>\n\n\tBarnabas GD, Bhat TA, Goebeler V, Maxwell CM, Reid GS, Senger D, Parker S, Bush J, Strahlendorf C, Deyell R, Lim CJ, Lange PF, and on behalf of the PROFYLE program. Prioritizing treatment targets for a rare pediatric malignancy using proteomics and personalized xenograft models within an actionable timeframe. Zero Childhood Cancer (ZERO) National Symposium. Oct, 2022 (Poster & Rapid-Fire Talk)<\/li>\n\n\tRolf N, Liu LYT, Tsang A, Vercauteren SM, Reid GSD. Stability of leukemia immunophenotypes through disease progression. BCCHR Childhood Diseases Theme Symposium. Oct, 2022 (Poster)<\/li>\n\n\tLorentzian A, Guo M, Ergin EK, Akella N, Rolf N, Leclair P, Goebeler V, Reid GSD, Lim CJ, Maxwell CA, and Lange PF. Proteogenomic analysis identifies the persistence of targetable genomes and proteomes through disease evolution in pediatric acute lymphoblastic leukemia. International Society of Pediatric Oncology (SIOP) Conference Barcelona, Spain. Sept, 2022 (Poster & Discussion Panel)<\/li>\n\n\tLorentzian A, Guo M, Ergin EK, Akella N, Rolf N, Leclair P, Goebeler V, Reid GSD, Lim CJ, Maxwell CA, and Lange PF. Persistence of targetable lesions and proteomes through disease evolution in pediatric acute lymphoblastic leukemia. Canadian National Proteomics Network (CNPN) Conference Montreal, QC. May, 2022 (Oral Presentation)<\/li>\n\n\tLeclair P, Lorentzian A, Rolf N, Goebeler V, Lange P, Maxwell C, Reid G, and Lim CJ. A Pre-Clinical Platform to Assess Efficacy for Precision Molecular Targeted Therapies in Pediatric Acute Lymphoblastic Leukemia. SIOP 2021 Virt Congress. Oct, 2021 (Poster)<\/li>\n\n\tRolf N, Liu LYT, Lorentzian A, Leclair P, Goebeler V, Lange PF, Lim CJ, Maxwell CA, Vercauteren SM, Reid GSD. Longitudinal assessment of phenotypic heterogeneity and subpopulation trajectories in B-ALL disease progression samples, 53rd Congress of the International Society of Pediatric Oncology (SIOP, Virtual). Pediatric Blood and Cancer (2021), 68: S166, #1443, Oct 2021 (Poster).<\/li>\n\n\tLorentzian A, Akella N, Rolf N, Leclair P, Goebeler V, Reid GSD, Lim CJ, Maxwell CA, and Lange PF. Persistence of proteomes, targetable lesions, and therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia. International Society of Pediatric Oncology (SIOP) Conference (Virtual) Sept, 2021 (Poster).<\/li>\n\n\tLorentzian A, Rolf N, Leclair P, Akella N, Gregor S.D. Reid GSD, Lim CJ, Maxwell CA, and Lange PF. Persistence of targetable lesions, proteome state, and predicted drug sensitivity through disease progression in pediatric acute lymphoblastic leukemia. Canadian National Proteomics Network (CNPN) Conference (Virtual) May, 2021. (Oral Presentation).<\/li>\n\n\tRolf N, Tsang A, Liu LYT, Lorentzian A, Leclair P, Patterson A, Lange PF, Maxwell CA, Lim CJ, Klein-Geltink R, Vercauteren SM, Reid GSD. MRD Xenotransplantation Prospectively Identifies Treatment-Selected Acute Lymphoblastic Leukemia Subpopulations with Relapse-Initating Potential, 63rd Annual Meeting of the American Society of Hematology (ASH, Virtual). Blood 136, S1: 12-13. Dec, 2020 (Poster).\u00a0<\/li>\n\n\tRolf N, Liu LYT, Tsang A, Vercauteren SM, Reid GSD. A cross-standardized analytical platform to permit comparison of immunophenotypic subpopulations between acute lymphoblastic leukemia patients and their patient-derived xenografts, Annual Meeting of the International Clinical Cytometry Society (ICCS, Virtual). Sept, 2020 (Poster; *1 out 5 Panelists selected for Virtual Poster Walk)<\/li>\n\n\tLorentzian A, Rolf N, Reid GSD, Lim CJ, Lange PF and Maxwell CA. Accounting for the Unique Molecular Landscape of Pediatric Malignancies Improves Target-Agent Pair Identification for Pediatric Precision Oncology. American Society of Hematology (ASH), San Diego, USA. Dec, 2018. (Poster)<\/li>\n\n\tUzozie A, Ergin E, Lorentzian A, Rolf N, Lim CJ, Reid G, Maxwell CA, and Lange PF. Patient-derived xenograft models recapitulate the proteome and functional capacity of primary pediatric acute lymphoblastic leukemia but divert in select pathways. International Society of Pediatric Oncology (SIOP) Conference (Virtual) Sept, 2021 (Poster).<\/li>\n<\/ol><\/div>\n<\/div><\/div>\n\n\n
      \n\t
      \n\t
      \n\t
      \n\t

      News<\/h2>

      The BRAvE Initiative in the news.<\/p>News<\/a><\/div>\n

      \n\t
      \n\t<\/figure>\n<\/div>\n<\/div><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":8,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_lmt_disableupdate":"","_lmt_disable":"","inline_featured_image":false,"footnotes":"","fndry_alternate_title":"Alternate Title!"},"class_list":["post-1215","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.bcchr.ca\/brave-initiative\/wp-json\/wp\/v2\/pages\/1215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bcchr.ca\/brave-initiative\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bcchr.ca\/brave-initiative\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bcchr.ca\/brave-initiative\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bcchr.ca\/brave-initiative\/wp-json\/wp\/v2\/comments?post=1215"}],"version-history":[{"count":7,"href":"https:\/\/www.bcchr.ca\/brave-initiative\/wp-json\/wp\/v2\/pages\/1215\/revisions"}],"predecessor-version":[{"id":2570,"href":"https:\/\/www.bcchr.ca\/brave-initiative\/wp-json\/wp\/v2\/pages\/1215\/revisions\/2570"}],"wp:attachment":[{"href":"https:\/\/www.bcchr.ca\/brave-initiative\/wp-json\/wp\/v2\/media?parent=1215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}